Skip to main content
SpringerLink
Log in

Prevention of coronary heart disease in diabetes

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Cardiovascular disease (especially coronary heart disease [CHD]) is the most common complication and cause of death in patients with type 2 diabetes. CHD prevention should be the major focus in preventive care of diabetes patients. There is a solid evidence base from which to recommend aggressive control of elevated blood pressure and lipids to reduce CHD events in diabetes. Aggressive glycemic control alone will not reduce CHD events, but will prevent diabetes-specific microvascular complications. Blood pressure should be treated to a goal of at least 130/80 mm Hg, and possibly lower, using angiotensin-converting enzyme inhibitors, thiazide diuretics, or β blockers as first-line agents. Low-density lipoprotein cholesterol should be treated with a statin to reduce the level by 30% to 40%, regardless of pretreatment level, to a goal of less than 100 mg/dL for most patients or a goal of less than 70 mg/dL in diabetes patients with CHD. Patients with high-density lipoprotein levels less than 40 mg/dL may benefit from fibrate therapy. Cigarette smoking should be actively discouraged, and prophylactic aspirin therapy should be prescribed for most patients. A regular program of physical activity and weight control should be prescribed to improve insulin sensitivity. Use of thiazolidinediones may be considered early in the course of hypoglycemic therapy, but additional research is needed to define the role of insulin sensitization as a primary means to reduce CHD risk in type 2 diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Harris MI, Flegal KM, Cowie CC, et al.: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care 1998, 21:518–524.

    Article  PubMed  CAS  Google Scholar 

  2. Kannel WB, McGee DL: Diabetes and cardiovascular disease: the Framingham Study. JAMA 1979, 241:2035–2038.

    Article  PubMed  CAS  Google Scholar 

  3. Wingard DL, Barrett-Connor E: Heart disease and diabetes. In Diabetes in America, edn 2. Edited by Harris M. Bethesda, MD: National Institutes of Health; 1995:429–456.

    Google Scholar 

  4. Miettinen H, Lehto S, Salomaa V, et al.: Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care 1998, 21:69–75.

    Article  PubMed  CAS  Google Scholar 

  5. Turner R, Cull C, Holman R: United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996, 124(1Pt 2):136–145.

    PubMed  CAS  Google Scholar 

  6. Fox CS, Coady S, Sorlie PD, et al.: Trends in cardiovascular complications of diabetes. JAMA 2004, 292:2495–2499. Analysis of Framingham Heart Study data shows that although patients with diabetes have had an approximately 50% reduction in CHD death in the United States over the past several decades, the RR for CHD remains approximately twofold higher than for nondiabetic Americans, highlighting the ongoing need for aggressive CHD risk factor reduction in diabetes.

    Article  PubMed  CAS  Google Scholar 

  7. Nathan DM: Some answers, more controversy, from UKPDS. Lancet 1998, 352:832–833.

    Article  PubMed  CAS  Google Scholar 

  8. Meigs JB, Mittleman MA Nathan DM, et al.: Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000, 283:221–228.

    Article  PubMed  CAS  Google Scholar 

  9. Haire-Joshu D, Glasgow RE, Tibbs TL: Smoking and diabetes. Diabetes Care 1999, 22:1887–1898.

    Article  PubMed  CAS  Google Scholar 

  10. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560–2572.

    Article  PubMed  CAS  Google Scholar 

  11. Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel HI guidelines. Circulation 2004, 110:227–239. The key review reference supporting more aggressive LDLC goals for CHD prevention in diabetes.

    Article  PubMed  Google Scholar 

  12. AmericanDiabetes Association: Standards of Medical Care in Diabetes. Diabetes Care 2005, 28:S4-S36. The key review reference providing overall strategies for CHD prevention in diabetes.

    Article  Google Scholar 

  13. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group [no authors listed]. BMJ 1998, 317:703–713.

  14. Adler A, Stratton I, McElroy H, et al.: Risk of macrovascular and microvascular complications of diabetes at different levels of blood pressure—observations from the UKPDS. Diabetes 1999, 48(suppl l):A063.

    Google Scholar 

  15. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group [no authors listed]. JAMA 2002, 288:2981–2997.

  16. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group [no authors listed]. BMJ 1998, 317:713–720.

  17. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet 1999, 353:611–616.

    Article  PubMed  CAS  Google Scholar 

  18. Lindholm LH, Ibsen H, Dahlof B, et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004–1010.

    Article  PubMed  CAS  Google Scholar 

  19. Estacio RO, Jeffers BW, Hiatt WR, et al.: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998, 338:645–652.

    Article  PubMed  CAS  Google Scholar 

  20. Tatti P, Pahor M, Byington RP, et al.: Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998, 21:597–603.

    Article  PubMed  CAS  Google Scholar 

  21. Tuomilehto J, Rastenyte D, Birkenhager WH, et al.: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999, 340:677–684.

    Article  PubMed  CAS  Google Scholar 

  22. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351:1755–1762.

    Article  PubMed  CAS  Google Scholar 

  23. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Study Investigators [no authors listed]. N Engl J Med 2000, 342:145–153.

  24. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. The Heart Outcomes Study Investigators [no authors listed]. Lancet 2000, 355:253–259.

  25. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869.

    Article  PubMed  CAS  Google Scholar 

  26. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N EnglJ Med 2001, 345:851–860.

    Article  CAS  Google Scholar 

  27. Pyorala K, Pedersen TR, Kjekshus J, et al.: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary artery disease. A sub-group analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997, 20:614–620.

    Article  PubMed  CAS  Google Scholar 

  28. Sacks FM, Pfeffer MA, Moye LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001–1009.

    Article  PubMed  CAS  Google Scholar 

  29. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group [no authors listed]. N Engl J Med 1998, 339:1349–1357.

  30. Collins R, Armitage J, Parish S, et al.: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005–2016.

    Article  PubMed  Google Scholar 

  31. Colhoun HM, Betteridge DJ, Durrington PN, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685–696.

    Article  PubMed  CAS  Google Scholar 

  32. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 341:410–418.

    Article  PubMed  CAS  Google Scholar 

  33. Koskinen P, Manttari M, Manninen V, et al.: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992, 15:820–825.

    Article  PubMed  CAS  Google Scholar 

  34. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. The Diabetes Atherosclerosis Intervention Study Investigators [no authors listed]. Lancet 2001, 357:905–910.

  35. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study Group [no authors listed]. Lancet 1998, 352:837–853.

  36. Gaede P, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383–393. The intensive surveillance and follow-up used in “Steno II” should become the standard of type 2 diabetes care in the United States, but would require substantially greater resources than are often available.

    Article  PubMed  Google Scholar 

  37. Rewers M, Zaccaro D, D’Agostino R, et al.: Insulin sensitivity, insulinemia, and coronary artery disease: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2004, 27:781–787.

    Article  PubMed  CAS  Google Scholar 

  38. Haffner SM, Mykkanen L, Festa A et al.: Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000, 101:975–980.

    PubMed  CAS  Google Scholar 

  39. Meigs JB, Hu FB, Rifai N, Manson JE: Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004, 291:1978–1986.

    Article  PubMed  CAS  Google Scholar 

  40. Irwin ML, Mayer-Davis EJ, Addy CL, et al.: Moderateintensity physical activity and fasting insulin levels in women: the Cross-Cultural Activity Participation Study. Diabetes Care 2000, 23:449–454.

    Article  PubMed  CAS  Google Scholar 

  41. Shadid S, Jensen MD: Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 2003, 26:3148–3152.

    Article  PubMed  CAS  Google Scholar 

  42. Wei M, Gibbons LW, Kampert JB, et al.: Low cardiorespiratory fitness and physical inactivity as predictors of mortality in men with type 2 diabetes. Ann Intern Med 2000, 132:605–611.

    PubMed  CAS  Google Scholar 

  43. Thompson PD, Buchner D, Pina IL, et al.: Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003, 107:3109–3116.

    Article  PubMed  Google Scholar 

  44. Frias JP, Yu JG, Kruszynska YT, Olefsky JM: Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects. Diabetes Care 2000, 23:64–69.

    Article  PubMed  CAS  Google Scholar 

  45. Haffner SM, Greenberg AS, Weston WM, et al.: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002, 106:679–684.

    Article  PubMed  CAS  Google Scholar 

  46. Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 2004, 351:1106–1118.

    Article  PubMed  Google Scholar 

  47. Chiquette E, Ramirez G, Defronzo R: A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004, 164:2097–2104.

    Article  PubMed  CAS  Google Scholar 

  48. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC: Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004, 24:930–934.

    Article  PubMed  CAS  Google Scholar 

  49. Minamikawa J, Tanaka S, Yamauchi M, et al.: Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998, 83:1818–1820.

    Article  PubMed  CAS  Google Scholar 

  50. Koshiyama H, Shimono D, Kuwamura N, et al.: Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001, 86:3452–3456.

    Article  PubMed  CAS  Google Scholar 

  51. Pistrosch F, Passauer J, Fischer S, et al.: In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004, 27:484–490.

    Article  PubMed  CAS  Google Scholar 

  52. Natali A, Baldeweg S, Toschi E, et al.: Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 2004, 27:1349–1357.

    Article  PubMed  CAS  Google Scholar 

  53. Masoudi FA, Inzucchi SE, Wang Y, et al.: Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005, 111:583–590.

    Article  PubMed  CAS  Google Scholar 

  54. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:854–865.

  55. Chiasson JL, Josse RG, Gomis R, et al.: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003, 290:486–494.

    Article  PubMed  CAS  Google Scholar 

  56. Meigs JB, Nathan DM, D’Agostino RB, Wilson PW: Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002, 25:1845–1850.

    Article  PubMed  Google Scholar 

  57. Prasad A, Quyyumi AA: Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation 2004, 110:1507–1512.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. General Internal Medicine Unit, Massachusetts General Hospital, 50 Staniford Street, 9th Floor, 02114, Boston, MA, USA

    James B. Meigs MD, MPH

Authors
  1. James B. Meigs MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meigs, J.B. Prevention of coronary heart disease in diabetes. Curr Treat Options Cardio Med 7, 259–271 (2005). https://doi.org/10.1007/s11936-005-0037-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-005-0037-8

Keywords

Search

Navigation